The remote patient monitoring (RPM) technology that a patient uses while receiving hospital-at-home care does not follow a ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period. The diabetes-focused company disappointed investors last year due to ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the performance of many top stocks reflects this reality. DexCom (NASDAQ: DXCM) is one ...

New research suggests that wearing continuous glucose monitors could lower the risk of dementia. Experts discuss how symptoms can overlap between diabetes and dementia.

A Breakthrough Over-the-Counter Glucose Biosensor In an era where proactive health management is more critical than ever, ...

Remember when tracking your steps felt revolutionary? Well, CGMs are taking health monitoring to a whole new level.

Some experts claim that reducing fluctuations throughout the day can help protect against heart disease, even for people who ...

Shares of DexCom, Inc. (NASDAQ:DXCM – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the ...

(Nasdaq:TRIB) announced new pre-pivotal clinical data supporting its next-generation continuous glucose monitor (CGM) system.

In a new study, researchers found that time-in-range for healthy blood sugar could be a viable marker of glycemic control and potentially could be used to predict complications of type 1 diabetes.

The FDA’s framework for AI regulation, while robust for premarket evaluation, would benefit from more specific mechanisms for continuous monitoring of AI performance in diverse real-world settings.

Diabetic students often have glucose monitors connected to phone apps that sound an alarm when they detect a problem, but ...